866-997-4948(US-Canada Toll Free)

Taxol (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 29 Pages

 

GlobalDatas pharmaceuticals report, Taxol (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Taxol sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Taxol including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Taxol including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2002-2017 for Taxol in the US, EU-5, Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 7
2.3.4 Other Environmental Agents 7
2.4 GlobalData Market Forecasts Report Guidance 8


3 NSCLC Disease Market: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecast and CAGR 9
3.3 Drivers for the NSCLC Disease Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapies 11
3.3.5 Promising Pipeline Drugs 11


4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Taxol 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Taxol 16
5.5 Factors Affecting Sales 16
5.5.1 Patent Expiry 16
5.5.2 Emergence of Targeted Therapies 16
5.5.3 Increasing Competition 16
5.5.4 Drug Administration 17
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 17
5.6.2 Safety 17
5.6.3 Compliance 17
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales forecast 18
5.8.1 Target patient Pool of Taxol 18
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projection of Taxol 20


6 Appendix 25
6.1 Market Definitions 25
6.2 Abbreviations 25
6.3 Research Methodology 25
6.3.1 Coverage 25
6.3.2 Secondary Research 26
6.3.3 Forecasting 26
6.3.4 Number of Patients Approved to take the Drug 26
6.3.5 Net Penetration of Drug 27
6.3.6 Net Annual Dosing 28
6.3.7 Annual Cost of Therapy 28
6.3.8 Primary Research 28
6.3.9 Expert Panels 28
6.4 Contact Us 29
6.5 Disclaimer 29
6.6 Sources 29

List of Table


Table 1: NSCLC Incidence and Mortality,20082030 5
Table 2: NSCLC, Estimated Global Market ($bn),20092020 9
Table 3: Results of Phase III First Line NSCLC Study 16
Table 4: Approval of Taxol by Indication 16
Table 5: Drug Risk Benefit Score of Taxol 17
Table 6: Annual Cost of Therapy of Taxol 19
Table 7: Taxol, NSCLC, Global, Sales Forecast ($m),20022009 20
Table 8: Taxol, NSCLC, Global, Sales Forecast ($m),20102017 20
Table 9: Taxol, NSCLC, The US, Sales Forecast ($m),20022009 21
Table 10: Taxol, NSCLC, The US, Sales Forecast ($m),20102017 21
Table 11: Taxol, NSCLC, EU, Sales Forecast ($m),20022009 22
Table 12: Taxol, NSCLC, EU, Sales Forecast ($m),20102017 22
Table 13: Taxol, NSCLC, Japan, Sales Forecast ($m),20022013 23

List of Chart


Figure 1: Percentage Distribution of the Top 20 Cancers 4
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors for NSCLC in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 8
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: Oncology,Global,Incidence(in million),20082030 10
Figure 8: NSCLC, Global, Incidence(in million),20082030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Drug Model Diagram of Taxol in The US, EU and Japan 18
Figure 13: Taxol, NSCLC, Global, Sales Forecast ($m),20022017 20
Figure 14: Taxol, NSCLC, The US, Sales Forecast ($m),2002-2017 21
Figure 15: Taxol, NSCLC, EU, Sales Forecast ($m),2002-2017 22
Figure 16: Taxol, NSCLC, Japan, Sales Forecast ($m),2002-2013 23
Figure 17: Taxol ,NSCLC, Global Sales Distribution by Country ($m), 2020 24
Figure 18: GlobalData Methodology 25
Figure 19: Drug Model Diagram 27
Figure 20: Patients Approved to take the Drug 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *